×
About 2,928 results

ALLMedicine™ Brain Cancer Center

Research & Reviews  905 results

Investigation of functionalized nanoplatforms using branched-ligands with different cha...
https://doi.org/10.1080/1061186X.2022.2077948
Journal of Drug Targeting; Wang S, Yang Z et. al.

May 14th, 2022 - Glioblastoma, a common malignancy of the central nervous system, which is the most destructive type of brain cancer. Clinical treatment remains a major challenge due to high infiltrative growth and the presence of the blood brain barrier (BBB). Th...

Long-term exposure to wildfires and cancer incidence in Canada: a population-based obse...
https://doi.org/10.1016/S2542-5196(22)00067-5
The Lancet. Planetary Health; Korsiak J, Pinault L et. al.

May 14th, 2022 - Wildfires emit many carcinogenic pollutants that contaminate air, water, terrestrial, and indoor environments. However, little is known about the relationship between exposure to wildfires and cancer risk. We aimed to assess the associations betwe...

Venous thromboembolic events in glioblastoma patients: an epidemiological study.
https://doi.org/10.1111/ene.15404
European Journal of Neurology; Eisele A, Seystahl K et. al.

May 13th, 2022 - Venous thromboembolic events (VTE) are a major complication in cancer patients, and therefore, also in brain cancer patients, anticoagulants are considered appropriate in the treatment of VTE. Frequency, risk factors and treatment of VTE, as well ...

The EAN Brain Health Strategy: One Brain, One Life, One Approach.
https://doi.org/10.1111/ene.15391
European Journal of Neurology; Bassetti CLA, Endres M et. al.

May 12th, 2022 - Brain health is essential for health, well-being productivity and creativity across the entire life. Its definition goes beyond the absence of disease embracing all cognitive, emotional, behavioural and social functions which are necessary to cope...

Combinatorial therapeutic strategies for enhanced delivery of therapeutics to brain can...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9090367
Drug Delivery; Wang X, Wu C et. al.

May 10th, 2022 - Brain cancer is the most aggressive one among various cancers. It has a drastic impact on people's lives because of the failure in treatment efficacy of the currently employed strategies. Various strategies used to relieve pain in brain cancer pat...

see more →

Guidelines  1 results

Clinical practice guidelines for the management of adult diffuse gliomas.
https://doi.org/10.1016/j.canlet.2020.10.050
Cancer Letters; Jiang T, Nam DH et. al.

Nov 10th, 2020 - To follow the revision of the fourth edition of WHO classification and the recent progress on the management of diffuse gliomas, the joint guideline committee of Chinese Glioma Cooperative Group (CGCG), Society for Neuro-Oncology of China (SNO-Chi...

see more →

Clinicaltrials.gov  38 results

T Cells Expressing HER2-specific Chimeric Antigen Receptors(CAR) for Patients With HER2-Positive CNS Tumors
https://clinicaltrials.gov/ct2/show/NCT02442297

May 6th, 2022 - First, to find out if HER2 is expressed in the patient's brain cancer, the investigators will need to obtain the tissue block or tissue specimen that was used to make the original diagnosis. If there is enough material, investigators may also look...

Pilot Study of a Metabolic Nutritional Therapy for the Management of Primary Brain Tumors
https://clinicaltrials.gov/ct2/show/NCT01535911

May 2nd, 2022 - Summary: The current standard of care for glioblastoma multiforme (GBM), the most common primary brain tumor in adults, includes surgical resection, radiation and chemotherapy. Survival rarely exceeds 18 months. The investigators propose to test t...

NG101m Adjuvant Therapy in Glioblastoma Patients
https://clinicaltrials.gov/ct2/show/NCT04373785

Apr 26th, 2022 - Glioblastoma multiforme (GBM) is the most lethal form of malignant brain cancer, with about 12,000 new cases diagnosed each in the the United States. The current standard treatment consists of maximal, safe resection, followed by radiation therapy...

Testing the Ability of AMG 232 (KRT 232) to Get Into the Tumor in Patients With Brain Cancer
https://clinicaltrials.gov/ct2/show/NCT03107780

Apr 11th, 2022 - PRIMARY OBJECTIVES: I. Determine the concentration and variability in concentration of navtemadlin (AMG 232 [KRT 232]) in brain and brain-associated tissue in patients with recurrent glioblastoma (GBM). (Part 1) II. Determine the maximum tolerated...

Safety Study of Pritumumab in Brain Cancer
https://clinicaltrials.gov/ct2/show/NCT04396717

Apr 11th, 2022 - This is an open-label, Phase 1, outpatient, dose escalation study of Pritumumab in patients with brain cancer who have failed prior therapy and have no other available options. In the first part of the study, escalating doses of Pritumumab of 1.6,...

see more →

News  225 results

Targeted Combo Notches Rare Success in Glioblastoma
https://www.onclive.com/view/targeted-combo-notches-rare-success-in-glioblastoma

Mar 30th, 2022 - For more than 20 years, investigators have tried numerous targeted therapy strategies against glioblastoma (GBM) that have fallen frustratingly short in establishing clinical benefit.1 That changed in November 2021 when an international team of in...

Cancer: Seeds of Destruction Developed To Attack Brain Tumour Cells
https://www.medscape.com/viewarticle/967583

Feb 3rd, 2022 - Researchers from University College London (UCL) have developed a new technique that combines thermal ablation of cancer cells with magnetic resonance navigation (MRN) to deliver implanted ferromagnetic thermoseeds to the precise site of a brain t...

Biden's 'Cancer Moonshot' About to Be Relaunched
https://www.medscape.com/viewarticle/967810

Feb 3rd, 2022 - The "Cancer Moonshot" is about to be relaunched! In a White House briefing, President Joe Biden announced that he is "reigniting" the initiative he spearheaded when he was Vice President during the Obama administration. During the livestreamed eve...

GLORIA Trial Examining NOX-A12 Plus Radiotherapy/Bevacizumab in Glioblastoma Safe to Continue Recruitment
https://www.onclive.com/view/gloria-trial-examining-nox-a12-plus-radiotherapy-bevacizumab-in-glioblastoma-safe-to-continue-recruitment

Jan 11th, 2022 - The Data Safety Monitoring Board has determined that it is safe and appropriate to continue recruitment to the expansion arm of the phase 1/2 GLORIA trial (NCT04121455), which is examining a novel combination comprised of NOX-A12 (olaptesed pegol)...

Sharp Fall in Cancer Clinical Trial Recruitment
https://www.medscape.com/viewarticle/964434

Dec 9th, 2021 - Recruitment to cancer clinical trials in England fell by 59% during the first year of the pandemic, according to experts. The Institute of Cancer Research (ICR) said COVID-19 had exacerbated long-standing issues with trial funding, regulation, and...

see more →

Patient Education  2 results see all →